Lutz D - Search Results

1

A randomized study comparing interferon (IFN alpha) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia (CML).

Kühr T, Burgstaller S, Apfelbeck U, Linkesch W, Seewann H, Fridrik M, Michlmayr G, Krieger O, Lutz D, Lin W, Pont J, Köck L, Abbrederis K, Baldinger C, Buder R, Geissler D, Hausmaninger H, Lang A, Zabernigg A, Duba C, Hilbe W, Eisterer W, Fiegl M, Greil R, Gastl G, Thaler J; Austrian CML Study Group. Kühr T, et al. Among authors: lutz d. Leuk Res. 2003 May;27(5):405-11. doi: 10.1016/s0145-2126(02)00223-0. Leuk Res. 2003. PMID: 12620292 Clinical Trial.

2

All-trans retinoic acid and short-time, high-dose cytarabine in two children with acute promyelocytic leukemia.

Schmitt K, Zoubek A, Schwarz R, Tulzer G, Koller E, Krieger O, Lutz D, Gadner H. Schmitt K, et al. Among authors: lutz d. Med Pediatr Oncol. 1996 Apr;26(4):254-7. doi: 10.1002/(SICI)1096-911X(199604)26:4<254::AID-MPO6>3.0.CO;2-I. Med Pediatr Oncol. 1996. PMID: 8600337

3

Remission may continue after termination of rIFN alpha-2b treatment for essential thrombocythemia.

Kasparu H, Bernhart M, Krieger O, Lutz D. Kasparu H, et al. Among authors: lutz d. Eur J Haematol. 1992 Jan;48(1):33-6. doi: 10.1111/j.1600-0609.1992.tb01790.x. Eur J Haematol. 1992. PMID: 1730277

4

The clinical impact of DNA methylation frequencies of JAK2 negative regulators in patients with essential thrombocythemia.

Födermayr M, Zach O, Huber M, Machherndl-Spandl S, Wölfl S, Bösmüller HC, Hasenschwandtner S, Burgstaller S, Krieger O, Lutz D, Weltermann A, Hauser H. Födermayr M, et al. Among authors: lutz d. Leuk Res. 2012 May;36(5):588-90. doi: 10.1016/j.leukres.2012.01.008. Epub 2012 Feb 9. Leuk Res. 2012. PMID: 22325365

5

Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia.

Koller E, Karlic H, Krieger O, Mistrik M, Michlmayr G, Gadner H, Lutz D, Heinz R, Pittermann E. Koller E, et al. Among authors: lutz d. Ann Hematol. 1995 Feb;70(2):75-8. doi: 10.1007/BF01834383. Ann Hematol. 1995. PMID: 7880927

6

Clonal evolution in a transforming 5q- syndrome.

Kandioler D, Krieger O, Nowotny H, Lutz D. Kandioler D, et al. Among authors: lutz d. Leukemia. 1994 Apr;8(4):711-2. Leukemia. 1994. PMID: 8152269 No abstract available.

7

Preliminary results of an induction combination regimen including fractionated anthracycline.

Krieger O, Bernhart M, Fiedler E, Kasparu H, Weber E, Lutz D. Krieger O, et al. Among authors: lutz d. Bone Marrow Transplant. 1989 Dec;4 Suppl 3:66. Bone Marrow Transplant. 1989. PMID: 2627610 No abstract available.

8

OCT1 (SLC22A1) R61C polymorphism and response to imatinib treatment in chronic myeloid leukemia patients.

Zach O, Krieger O, Foedermayr M, Zellhofer B, Lutz D. Zach O, et al. Among authors: lutz d. Leuk Lymphoma. 2008 Nov;49(11):2222-3. doi: 10.1080/10428190802322893. Leuk Lymphoma. 2008. PMID: 19021069 No abstract available.

9

Restoration of all-trans retinoic acid sensitivity by interferon in acute promyelocytic leukaemia.

Koller E, Krieger O, Kasparu H, Lutz D. Koller E, et al. Among authors: lutz d. Lancet. 1991 Nov 2;338(8775):1154-5. doi: 10.1016/0140-6736(91)92021-s. Lancet. 1991. PMID: 1682582 No abstract available.

10

[Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy].

Kasparu H, Krieger O, Bettelheim P, Kolb A, Lutz D. Kasparu H, et al. Among authors: lutz d. Wien Med Wochenschr. 1995;145(2-3):58-60. Wien Med Wochenschr. 1995. PMID: 7539197 German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

280 results

Search Page